325 related articles for article (PubMed ID: 20520718)
21. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma.
Grossman D; McNiff JM; Li F; Altieri DC
J Invest Dermatol; 1999 Dec; 113(6):1076-81. PubMed ID: 10594755
[TBL] [Abstract][Full Text] [Related]
22. Decreased expression of Apaf-1 with progression of melanoma.
Mustika R; Budiyanto A; Nishigori C; Ichihashi M; Ueda M
Pigment Cell Res; 2005 Feb; 18(1):59-62. PubMed ID: 15649154
[TBL] [Abstract][Full Text] [Related]
23. Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin.
Kanitakis J; Narvaez D; Claudy A
Melanoma Res; 2002 Jun; 12(3):241-4. PubMed ID: 12140380
[TBL] [Abstract][Full Text] [Related]
24. Deregulation of glyceraldehyde-3-phosphate dehydrogenase expression during tumor progression of human cutaneous melanoma.
Ramos D; Pellín-Carcelén A; Agustí J; Murgui A; Jordá E; Pellín A; Monteagudo C
Anticancer Res; 2015 Jan; 35(1):439-44. PubMed ID: 25550585
[TBL] [Abstract][Full Text] [Related]
25. Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine.
Takeuchi H; Morton DL; Elashoff D; Hoon DS
Int J Cancer; 2005 Dec; 117(6):1032-8. PubMed ID: 15986442
[TBL] [Abstract][Full Text] [Related]
26. DNA hypermethylation is associated with invasive phenotype of malignant melanoma.
Koroknai V; Szász I; Hernandez-Vargas H; Fernandez-Jimenez N; Cuenin C; Herceg Z; Vízkeleti L; Ádány R; Ecsedi S; Balázs M
Exp Dermatol; 2020 Jan; 29(1):39-50. PubMed ID: 31602702
[TBL] [Abstract][Full Text] [Related]
27. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
Garraway LA; Widlund HR; Rubin MA; Getz G; Berger AJ; Ramaswamy S; Beroukhim R; Milner DA; Granter SR; Du J; Lee C; Wagner SN; Li C; Golub TR; Rimm DL; Meyerson ML; Fisher DE; Sellers WR
Nature; 2005 Jul; 436(7047):117-22. PubMed ID: 16001072
[TBL] [Abstract][Full Text] [Related]
28. Identification of key candidate genes involved in melanoma metastasis.
Chen J; Wu F; Shi Y; Yang D; Xu M; Lai Y; Liu Y
Mol Med Rep; 2019 Aug; 20(2):903-914. PubMed ID: 31173190
[TBL] [Abstract][Full Text] [Related]
29. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues.
Jaeger J; Koczan D; Thiesen HJ; Ibrahim SM; Gross G; Spang R; Kunz M
Clin Cancer Res; 2007 Feb; 13(3):806-15. PubMed ID: 17289871
[TBL] [Abstract][Full Text] [Related]
30. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
31. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
32. Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas.
Güvenç C; Antoranz A; Szumera-Ciećkiewicz A; Teterycz PP; Rutkowski PR; Rawson RV; Scolyer RA; Thompson JF; Newton-Bishop J; Stas M; Boecxstaens V; Bechter O; Vercauteren J; Garmyn M; van den Oord J; Bosisio FM
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638912
[TBL] [Abstract][Full Text] [Related]
33. Gab2-mediated signaling promotes melanoma metastasis.
Horst B; Gruvberger-Saal SK; Hopkins BD; Bordone L; Yang Y; Chernoff KA; Uzoma I; Schwipper V; Liebau J; Nowak NJ; Brunner G; Owens D; Rimm DL; Parsons R; Celebi JT
Am J Pathol; 2009 Apr; 174(4):1524-33. PubMed ID: 19342374
[TBL] [Abstract][Full Text] [Related]
34. Down-regulation of pro-apoptotic genes is an early event in the progression of malignant melanoma.
Jensen EH; Lewis JM; McLoughlin JM; Alvarado MD; Daud A; Messina J; Enkemann S; Yeatman TJ; Sondak VK; Riker AI
Ann Surg Oncol; 2007 Apr; 14(4):1416-23. PubMed ID: 17195911
[TBL] [Abstract][Full Text] [Related]
35. Loss of MDA-7 expression with progression of melanoma.
Ellerhorst JA; Prieto VG; Ekmekcioglu S; Broemeling L; Yekell S; Chada S; Grimm EA
J Clin Oncol; 2002 Feb; 20(4):1069-74. PubMed ID: 11844832
[TBL] [Abstract][Full Text] [Related]
36. PUMA expression is significantly reduced in human cutaneous melanomas.
Karst AM; Dai DL; Martinka M; Li G
Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057
[TBL] [Abstract][Full Text] [Related]
37. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis.
Riker AI; Enkemann SA; Fodstad O; Liu S; Ren S; Morris C; Xi Y; Howell P; Metge B; Samant RS; Shevde LA; Li W; Eschrich S; Daud A; Ju J; Matta J
BMC Med Genomics; 2008 Apr; 1():13. PubMed ID: 18442402
[TBL] [Abstract][Full Text] [Related]
38. Expression of microtubule-associated protein 2 in benign and malignant melanocytes: implications for differentiation and progression of cutaneous melanoma.
Fang D; Hallman J; Sangha N; Kute TE; Hammarback JA; White WL; Setaluri V
Am J Pathol; 2001 Jun; 158(6):2107-15. PubMed ID: 11395388
[TBL] [Abstract][Full Text] [Related]
39. Is nonmetastatic cutaneous melanoma predictable through genomic biomarkers?
Branca M; Orso S; Molinari RC; Xu H; Guerrier S; Zhang Y; Mili N
Melanoma Res; 2018 Feb; 28(1):21-29. PubMed ID: 29194095
[TBL] [Abstract][Full Text] [Related]
40. Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma.
Goto Y; Koyanagi K; Narita N; Kawakami Y; Takata M; Uchiyama A; Nguyen L; Nguyen T; Ye X; Morton DL; Hoon DS
J Invest Dermatol; 2010 Jan; 130(1):221-9. PubMed ID: 19587692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
